BioSpace News Archive

New TARGET- NASH data shows longitudinal trajectories of alanine aminotransferase (ALT) remained comparatively stable among patients with nonalcoholic fatty liver disease (NAFLD) in the latest real-world study by Target RWE.

Results demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity.

Clue Genetics Inc. (Clue) is pleased to announce the appointment of Dr. Peter P. Repetti as its Vice President of Research. He will oversee development of Clue’s foundational platform of intellectual property centered on fungal genomes and will lead the company’s research initiatives in metabologenomics.

Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%.

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Artelo’s Vice President of Translational Sciences, has been selected for an oral presentation at the 32nd International Cannabinoid Research Society (ICRS) Symposium.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCell’s lead candidate, Bria-IMT™.

AIkido Pharma Inc. announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries.

Propanc Biopharma, Inc. announced that the Company filed a Definitive Information Statement under Section 14C of the Exchange Act on June 9, 2022, to increase the authorized shares of common stock and the option to effectuate a reverse split of common stock at the discretion of the Board.

Vigo Health Technology has been invited to attend the International Assistive Technology for Life Expo, one of the biggest annual events in the health and wellness industry from August 4 to 7, 2022 in Taipei.